Engineered TCR and CAR Immunotherapeutics 2015

March 2015 | 201 pages | ID: E407C0B959EEN
La Merie Publishing

Abstracts

Engineered TCR and CAR Immunotherapeutics 2015:

A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs

The engineered T cell receptor (TCR) for targeting of intracellur targets not drug gable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Leveraging the power of T cells by cellular and recombinant immuno-therapeutics

• Intra-cellular Targets
• Cell surface targets
• Cellular
• TCR T Cells
• CAR T Cells (autologous/allogeneic)
• Recombinant
• Bispecific TCR-anti-CD3 (e.g. ImmTACs)
• Bispecific antibodies (incl. anti-CD3)

This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. Download Sample Pages: Engineered TCR and CAR Immunotherapeutics 2015

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

• Profiles of TCR and CAR immunotherapeutics in development;
• Competitor analysis of CD19 CAR T cells;
• Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value;
• Target analysis of TCR T cells in R&D;
• CAR T Cell pipeline in hematology;
• CAR T Cell pipeline in solid tumors;
• Allogeneic TCR and CAR T cells in R&D;
• Universal antibody-targeted CAR T cells and NK cells;
• Pipeline of most promising TILs, NK cells, DLIs and CTLs;
• Technologies needed for next generations of TCR and CAR immunotherapeutics;
• Profiles of biotechnology companies incl. financing and licensing/partnering;
• Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs;
• Stakeholder analysis (established, emerging, non-US, technology providing companies);
• Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs;
• Analysis of major partnering deals between Big pharma and technology companies;
• Economic terms of pharma-biotech deals;
• Opportunities for biotech-biotech deals in the TCR and CAR field;
• Potential to raise private money with TCR and CAR technologies;
• Success in initial public offerings and follow on offerings with TCRs and CARs;
• Limitations and hurdles with current TCR and CAR immunotherapeutics;
• Opportunities for novel TCR and CAR immunotherapeutics;
• Pricing of TCR and CAR immunotherapeutics;
• Aspects of manufacturing and commercialization.

Who will benefit from the report?

• Venture capital, private equity and investment managers;
• Financial analysts;
• CFO;
• Business development and licensing (BDL) specialists;
• Marketing managers;
• CEO, COO and managing directors;
• Corporate strategy, product and portfolio analysts and managers;
• Chief Technology Officer;
• Cell technology and manufacturing specialists;
• Clinical and preclinical development specialists.

Contents

1 INTRODUCTION

2 EXECUTIVE SUMMARY

3 PROFILES OF TCR & CAR IMMUNOTHERAPEUTICS, NK CELLS, TILS, DLIS AND CTLS

3.1 TCR Fusion Proteins & Antibodies
  ALT-801
  IMCgp100
  ESK1 / ESKM3.2
3.2 Autologous TCR T Cells for Solid Tumors & Hematologic Malignancies
  NY-ESOc259T
  JCAR016
  TBI-1201
  TBI-1301
  BPX-701
3.3 CD19 CAR T Cells
  CTL019
  HuCART19 (HuCTL019)
  JCAR015
  JCAR017
  JCAR014
  KTE-C19
  CD19-CAR T cells (Takara)
  BPX-401
3.4 Other Autologous CAR T Cells for Hematological Malignancies
  CART123
  CM-CS1
3.5 Autologous CAR T Cells for Solid Tumors
  G2-CAR.OX4028.z.ICD19
  BPX-601
  CAR-NKp30/B7H6
  CART-EGFRvIII
  CART-meso T cells
3.6 Allogeneic CAR T Cells
  UCART19
  UCART38
  UCART123
  UCARTCS1
3.7 Universal CAR T cells
  ATTCK20
3.8 NK Cells, TILs, DLIs & CTLs
  Natural Killer (NK) cells: Neukoplast / NK-92
  NK cells: CD16-Neukoplast
  NK cells: NK-92.ErbB2/Her2
  Tumor Infiltrating Lymphocytes (TILs): LN-144 (Contego)
  Donor Lymphocyte Infusion (DLI): BPX-501
  Cytotoxic T-Lymphocytes (CTLs): EBV-CTL

4 PIPELINE ANALYSIS

4.1 TCR Antibodies, Fusion Proteins and TCR-like Antibodies
4.2 TCR T-Cells
4.3 CD19 CAR T Cells
4.4 Other CAR T Cells for Hematological Malignancies
4.5 Other CAR T Cells for Solid Tumors
4.6 Allogeneic TCR & CAR T Cells
4.7 Universal, antibody-targeted CAR T Cells
4.8 Natural Killer cells (NK cells), Tumor Infiltrating Lymphocytes (TILs), Donor Lymphocyte Infusions (DLIs) and Cytotoxic T Lymphocytes (CTLs)

5 TECHNOLOGY COMPANIES

5.1 Adaptimmune
5.2 Altor Bioscience
5.3 Applied Immune Technologies (AIT)
5.4 Atara Biotherapeutics
5.5 Autolus
5.6 Bellicum Pharmaceuticals
5.7 Bluebird bio
5.8 Cardio3 BioSciences
5.9 Cellectis
5.10 Cellular Biomedicine Group (CBMG)
5.11 Conkwest
5.12 CRISPR Therapeutics
5.13 CytomX
5.14 Editas Medicine
5.15 Eureka Therapeutics
5.16 Immunocore
5.17 Intellia Therapeutics
5.18 Intrexon, ZIOPHARM Oncology & MD Anderson
5.19 Juno Therapeutics
5.20 Kite Pharma
5.21 Lion Biotechnologies
5.22 MD Anderson Cancer Center
5.23 Medigene
5.24 Nextera
5.25 Sorrento Therapeutics
5.26 Takara Bio
5.27 Transposagen Biopharmaceuticals
5.28 Unum Therapeutics

6 PHARMACEUTICAL COMPANIES

6.1 Amgen
6.2 AstraZeneca
6.3 Celgene
6.4 Eli Lilly
6.5 GlaxoSmithKline
6.6 Janssen Biotech
6.7 Novartis
6.8 Pfizer
6.9 Roche
6.10 Servier

7 STAKEHOLDER ANALYSIS

7.1 TCR Focused Companies
7.2 Established CAR (& TCR) T Cell Companies
7.3 Emerging and/or non-US based CAR (& TCR) T Cell Companies
7.4 Technology Providers
7.5. Pharma Companies in the Field
7.6 Companies with Alternative Adoptive Cell Therapies: NK Cells, TILs, DLIs & CTLs

8 SELECTED TECHNOLOGY PROFILES

8.1 Genome Editing Technologies
  Allogeneic multichain chimeric Antigen Receptor (mcCAR) T-cells
  CAR T cells and multiplex gene editing (bluebird bio)
  Genome Editing Technology (Transposagen)
8.2 Switch Technologies
  Inducible Caspase 9 and inducible MyD88/CD40 Switch Systems
  RheoSwitch Therapeutic System (RTS) technology
8.3 Non-Viral Gene Transfer
  Sleeping Beauty
8.4 Next Generation CAR T Cell Technologies
  Juno Therapeutics‘ CAR Technologies
8.5 Engineered TCR T Cells
  TCR Engineered T Cell Technology (Adaptimmune)
8.6 Special Cases of CAR T Cell Construcs
  Oncyte CAR T Cell Constructs
  Universal Antibody-Coupled T-cell Receptor (ACTR) technology

9 BUSINESS PERSPECTIVE ON TCR AND CAR IMMUNOTHERAPEUTICS

9.1 Deals
9.2 Private Financing Rounds
9.3 Public Offerings and Market Capitalization of Companies with TCR or CAR Immunotherapeutics

10 OUTLOOK FOR TCR AND CAR IMMUNOTHERAPEUTICS

10.1 Limitations and Hurdles with current CAR T Cell Therapies
10.2 Opportunities for Novel TCR and CAR Immunotherapeutics
10.3 Pricing of CAR and TCR T Cell Products
10.4 Manufacturing and Commercialization

11 REFERENCES